

5.60.058

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	January 1, 2024
<b>Subsection:</b>	Central Nervous System Drugs	<b>Original Policy Date:</b>	April 14, 2023
<b>Subject:</b>	Auvelity	<b>Page:</b>	1 of 4

---

**Last Review Date:** December 8, 2023

---

## Auvelity

### Description

#### Auvelity (dextromethorphan and bupropion)

##### Background

Auvelity is a combination of dextromethorphan, an uncompetitive N-methyl D-aspartate (NMDA) receptor antagonist and a sigma-1 receptor agonist, and bupropion, an aminoketone and cytochrome P450 2D6 inhibitor. Bupropion increases plasma levels of dextromethorphan by competitively inhibiting cytochrome P450 2D6, which catalyzes a major biotransformation pathway for dextromethorphan. Bupropion is a relatively weak inhibitor of neuronal reuptake of norepinephrine and dopamine and does not inhibit monoamine oxidase or the reuptake of serotonin. The mechanism of Auvelity in the treatment of major depressive disorder (MDD) is unclear (1).

##### Regulatory Status

FDA-approved indications: Auvelity is indicated for the treatment of major depressive disorder (MDD) in adults (1).

Auvelity has a boxed warning regarding increased risk of suicidal thoughts and behaviors in pediatric and young adult patients taking antidepressants. Antidepressant-treated patients should be closely monitored for clinical worsening and emergence of suicidal thoughts and behaviors (1).

Contraindications to Auvelity include the following: seizure disorder; current or prior diagnosis of bulimia or anorexia nervosa; abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs; and use with a monoamine oxidase inhibitor (MAOI) or within 14 days of stopping treatment (1).

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	January 1, 2024
<b>Subsection:</b>	Central Nervous System Drugs	<b>Original Policy Date:</b>	April 14, 2023
<b>Subject:</b>	Auvelity	<b>Page:</b>	2 of 4

---

The use of Auvelity has been associated with seizures, increased blood pressure, activation of mania or hypomania, psychosis and other neuropsychiatric reactions, and angle-closure glaucoma. Patients should be screened and monitored for these outcomes and the medication discontinued as medically indicated. The use of this medication in combination with selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants increase the risk of serotonin syndrome. If this occurs, the medication should be discontinued (1).

The components of Auvelity, dextromethorphan and bupropion, have abuse potential. Prescribers should proceed with caution in patients with a history of substance abuse and consider the risks and benefits of using Auvelity in this patient population (1).

Auvelity may cause fetal harm when administered to pregnant women. Pregnant women should be advised of the potential risk to a fetus. Discontinue treatment in pregnant females and use alternative treatment for females who are planning to become pregnant (1).

The safety and effectiveness of Auvelity in pediatric patients less than 18 years of age have not been established (1).

### Related policies

Spravato

### Policy

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

Auvelity may be considered **medically necessary** if the conditions indicated below are met.

Auvelity may be considered **investigational** for all other indications.

## Prior-Approval Requirements

**Age** 18 years of age or older

### Diagnosis

Patient must have the following:

1. Major depressive disorder (MDD)

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	January 1, 2024
<b>Subsection:</b>	Central Nervous System Drugs	<b>Original Policy Date:</b>	April 14, 2023
<b>Subject:</b>	Auvelity	<b>Page:</b>	3 of 4

---

**AND** the following:

- a. Patient has had an inadequate response, intolerance, or contraindication to at least **TWO** different antidepressants

## Prior – Approval *Renewal* Requirements

**Age** 18 years of age or older

### Diagnosis

Patient must have the following:

1. Major depressive disorder (MDD)

**AND** the following:

- a. Condition has improved or stabilized on therapy

### Policy Guidelines

## Pre - PA Allowance

None

## Prior - Approval Limits

**Quantity** 180 tablets per 90 days

**Duration** 12 months

## Prior – Approval *Renewal* Limits

Same as above

### Rationale

#### Summary

Auvelity is a combination of dextromethorphan and bupropion. Increased risk of suicidal thoughts and behavior in pediatric and young adult patients may occur. Auvelity should be discontinued in pregnant females due to risk of embryo-fetal toxicity. The safety and

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	January 1, 2024
<b>Subsection:</b>	Central Nervous System Drugs	<b>Original Policy Date:</b>	April 14, 2023
<b>Subject:</b>	Auvelity	<b>Page:</b>	4 of 4

---

effectiveness of Auvelity in pediatric patients less than 18 years of age have not been established (1).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Auvelity while maintaining optimal therapeutic outcomes.

## References

1. Auvelity [package insert]. New York, NY: Axsome Therapeutics, Inc.; December 2022.

## Policy History

Date	Action
April 2023	Addition to PA
June 2023	Annual review
December 2023	Annual review

## Keywords

**This policy was approved by the FEP® Pharmacy and Medical Policy Committee on December 8, 2023 and is effective on January 1, 2024.**